P-94  ERLOTINIB AS MAINTENANCE THERAPY IN ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): A SUBANALYSIS OF THE SATURN STUDY

Yi-Long Wu¹, Joo-Hang Kim², Keunchil Park³, Adel Zaatar⁴, Gaelle Klingelschmitt⁵, Christina Ng⁶

¹Guangdong General Hospital (GGH), Chinese Society of Lung Cancer, Guangdong General Hospital, China, ²Yonsei Cancer Centre, Korea, ³Samsung Medical Centre, Korea, ⁴Mount Miriam Hospital, Malaysia, ⁵F. Hoffmann-La Roche Ltd, Switzerland, ⁶Sunway Medical Centre, Malaysia

P-95  FIRST-LINE BEVACIZUMAB PLUS CHEMOTHERAPY IN CHINESE PATIENTS WITH ADVANCED OR RECURRENT NONSQUAMOUS NSCLC: SUBANALYSIS OF SAiL (MO19390)

Yi-Long Wu¹, Caicun Zhou², Guoliang Jiang³, Mengzhao Wang⁴, Zhongzhen Guan⁵, Chun-Ming Tsai⁶, Affiliation Group⁷

¹Guangdong General Hospital (GGH), Chinese Society of Lung Cancer, Guangdong General Hospital, China, ²Shanghai Pulmonary Hospital, China, ³Fudan University Cancer Hospital, China, ⁴Peking Union Medical College Hospital, China, ⁵Sun Yat-Sen University of Medical Science, China, ⁶Taipei Veterans General Hospital, Taiwan, ⁷on behalf of the SAiL investigators

P-96  ERLOTINIB IN >1,200 E/SE ASIAN PATIENTS WITH ADVANCED NON-SMALL-CELL LUNG CANCER (NSCLC): FINAL RESULTS OF THE TRUST STUDY

Tony Mok¹, Joseph Siu-Kie Au², Caicun Zhou³, Yi-Long Wu⁴, Li Zhang⁵, Reury-Perng Perng⁶, Keunchil Park⁷

¹Department of Oncology, Prince of Wales Hospital, Hong Kong, China, ²Department of Clinical Oncology, Queen Elizabeth Hospital, Hong Kong, China, ³Department of Oncology, Shanghai Pulmonary Hospital, China, ⁴Guangdong Lung Cancer Institute, Guangdong General Hospital, China;, ⁵Sun Yat-Sen University Cancer Centre, China, ⁶Taipei Veteran’s General Hospital, Taiwan, ⁷Samsung Medical Centre, Sungkyunkwan University School of Medicine, Korea

P-97  Induction chemotherapy followed by concurrent chemoradiotherapy in locally advanced inoperable head and neck cancer: feasibility and response in Indian context

Naresh Ratanlal Somani¹, P. Agarwal¹, R. Pasricha², N Khuteta³

¹Medical Oncology, Bhagwan Mahaveer Cancer Hospital, India, ²Department of Radiation Oncology, ³Department of Surgical Oncology

 YIA from Korean Cancer Association  P-98  A phase II trial of Gemcitabine, Ifosfamide, Dexamethasone, and Oxaliplatin (GIDOX) for patients with refractory or relapsed Non-Hodgkin’s Lymphoma

Byeong-Bae Park¹, Won Seog Kim², Hyeon Seok Eom³, Jin Seok Kim⁴, Suk Joong Oh⁵, In Gyu Hwang⁶, Cheolwon Suh⁷

¹Department of Internal Medicine, Hanyang University College of Medicine, Korea, ²Division of Hematology/Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Korea, ³Hematology/Oncology Clinic, Research Institute and Hospital, National Cancer Center, Korea, ⁴Division of Hematology, Department of Internal Medicine, Yonsei University College of Medicine, Korea, ⁵Department of Internal Medicine, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Korea, ⁶Division of Hematology-Oncology, Department of Internal Medicine, Chung-Ang University, School of Medicine, Korea, ⁷Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Korea

P-99  IS ARSENICTRIOXIDE USEFUL FOR THE TREATMENT OF ACUTE NON PROMYELOCYRIC MYELOID LEUKEMIA?

Iraj Asvadi Kermani, Farahnaz Ghahremanfard, Zohreh Sanaat, Roya Dolatkhah

Department of Hematology and Oncology, Tabriz University of Medical Sciences, Iran

P-100  CLINICAL DEVELOPMENT OF CATUMAXOMAB (REMOVAB) IN MALIGNANT ASCITES

Mirko M. Essing¹, Diane Seimetz², Anke Klein¹, Rolf Linke³

¹Medical Affairs, Fresenius Biotech GmbH, Germany, ²CSO, Fresenius Biotech GmbH, Germany, ³Clinical Development, Fresenius Biotech GmbH, Germany

↑ Page Top